IGFBP2 and prostate carcinoma: Moreover, overexpression of IGFBP2 has been associated with resistance to docetaxel or paclitaxel and anti-hormone therapy in prostate cancer, suggesting that IGFBP2 induced functional changes in cancer cells could play a critical role in the efficacy of anticancer therapy8.